Claims for Patent: 10,413,606

Summary for Patent: 10,413,606

Title:	Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies
Abstract:	This document provides methods and materials for treating cancer (e.g., skin cancer) with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies.
Inventor(s):	Markovic; Svetomir N. (Rochester, MN), Nevala; Wendy K. (Rochester, MN)
Assignee:	Mayo Foundation for Medical Education and Research (Rochester, MN)
Application Number:	14/432,979
Patent Claims:	1. A method for treating a mammal having a cancer, said method comprising administering to said mammal a therapeutically effective amount of a pharmaceutical composition comprising: a pharmaceutically acceptable carrier and an effective amount of preformed nanoparticle complexes comprising albumin, a bevacizumab antibody, and paclitaxel; wherein the preformed nanoparticle complexes have been pre-formed in vitro by combining aqueous albumin-paclitaxel nanoparticles with the bevacizumab antibody under conditions to form the preformed nanoparticle complexes; and said composition has been formed by combining the pre-formed nanoparticle complexes with the pharmaceutically acceptable carrier to form the pharmaceutical composition; wherein said cancer is skin cancer, cervical cancer, lung cancer, colorectal cancer, glioblastoma, ovarian cancer, or renal cancer; and further wherein the average diameter of said preformed nanoparticle complexes is between 0.1 .mu.m and 1 .mu.m. 2. The method of claim 1, wherein said mammal is a human. 3. The method of claim 1, wherein said cancer is melanoma. 4. The method of claim 1, wherein said cancer is stage IV melanoma. 5. The method of claim 1, wherein said composition or said nanoparticle complexes comprises an alkylating agent. 6. The method of claim 1, wherein the ratio of albumin-paclitaxel nanoparticles to the bevacizumab antibody is between 5:1 and 1:2.5. 7. The method of claim 1, wherein the pharmaceutical composition is administered by intravenous injection. 8. The method of claim 1, wherein the therapeutically effective amount is between about 50 mg/m.sup.2 and about 175 mg/m.sup.2 albumin-paclitaxel nanoparticles. 9. The method of claim 1, wherein the therapeutically effective amount is between about 30 mg/m.sup.2 and about 70 mg/m.sup.2 bevacizumab. 10. The method of claim 1, wherein the therapeutically effective amount is between about 5 mg/kg and about 20 mg/kg bevacizumab. 11. The method of claim 1, wherein the pharmaceutical composition is administered from about once a month to about three times a month. 12. The method of claim 1, wherein the pharmaceutical composition is administered three times per 28 day cycle for at least two cycles. 13. A method for inhibiting vascular endothelial growth factor (VEGF) in a mammal having a cancer, Wherein said method comprises administering to said mammal a therapeutically effective amount of a pharmaceutical composition comprising: a pharmaceutically acceptable carrier and an effective amount of preformed nanoparticle complexes comprising albumin, a bevacizumab antibody, and paclitaxel; wherein the nanoparticle complexes have been pre-formed in vitro by combining aqueous albumin-paclitaxel nanoparticles with the bevacizumab antibody under conditions to form the preformed nanoparticle complexes; and said composition has been formed by combining the preformed nanoparticle complexes with the pharmaceutically acceptable carrier to form the pharmaceutical composition; wherein said preformed complexes have antibody mediated VEGF binding specificity and further wherein the average diameter of said preformed nanoparticle complexes is between 0.1 .mu.m and 1 .mu.m. 14. The method of claim 13, wherein said mammal is a human. 15. The method of claim 13, wherein said cancer is skin cancer, cervical cancer, lung cancer, colorectal cancer, glioblastoma, ovarian cancer, or renal cancer. 16. The method of claim 15, wherein said skin cancer is melanoma. 17. The method of claim 15, wherein said skin cancer is stage IV melanoma. 18. The method of claim 13, wherein said composition or said nanoparticle complexes comprise an alkylating agent. 19. The method of claim 13, wherein the ratio of albumin-paclitaxel nanoparticles to the bevacizumab antibody is between 5:1 and 1:2.5. 20. The method of claim 13, wherein the pharmaceutical composition is administered by intravenous injection. 21. The method of claim 13, wherein the therapeutically effective amount is between about 50 mg/m.sup.2 and about 175 mg/m.sup.2 albumin-paclitaxel nanoparticles. 22. The method of claim 13, wherein the therapeutically effective amount is between about 30 mg/m.sup.2 and about 70 mg/m.sup.2 bevacizumab antibody. 23. The method of claim 13, wherein the therapeutically effective amount is between about 5 mg/kg and about 20 mg/kg bevacizumab antibody. 24. The method of claim 13, wherein the pharmaceutical composition is administered from about once a month to about three times a month. 25. The method of claim 13, wherein the pharmaceutical composition is administered three times per 28 day cycle for at least two cycles. 26. A method for inhibiting vascular endothelial growth factor (VEGF) in a mammal having a cancer, wherein said method comprises administering to said mammal a therapeutically effective amount of a pharmaceutical composition comprising: a pharmaceutically acceptable carrier and an effective amount of preformed nanoparticle complexes comprising albumin, a bevacizumab antibody, and paclitaxel; wherein the nanoparticle complexes have been pre-formed in vitro by mixing an albumin-paclitaxel nanoparticle with the bevacizumab antibody under conditions to form the preformed nanoparticle complexes; and said composition has been formed by combining the preformed nanoparticle complexes with the pharmaceutically acceptable carrier to form the pharmaceutical composition; wherein said preformed complexes have antibody mediated VEGF binding specificity and further wherein the average diameter of said preformed nanoparticle complexes is between 0.1 .mu.m and 0.9 .mu.m. 27. The method of claim 26, wherein said mammal is a human. 28. The method of claim 26, wherein said cancer is skin cancer, cervical cancer, lung cancer, colon cancer, ovarian cancer, or renal cancer. 29. The method of claim 28, wherein said skin cancer is melanoma. 30. The method of claim 28, wherein said skin cancer is stage IV melanoma. 31. The method of claim 26, wherein said composition or said nanoparticle complexes comprise an alkylating agent. 32. The method of claim 26, wherein the ratio of albumin-paclitaxel nanoparticles to the bevacizumab antibody is between 5:1 and 1:2.5. 33. The method of claim 26, wherein the pharmaceutical composition is administered by intravenous injection. 34. The method of claim 26, wherein the therapeutically effective amount is between about 50 mg/m.sup.2 and about 175 mg/m.sup.2 albumin-paclitaxel nanoparticles. 35. The method of claim 26, wherein the therapeutically effective amount is between about 30 mg/m.sup.2 and about 70 mg/m.sup.2 bevacizumab antibody. 36. The method of claim 26, wherein the therapeutically effective amount is between about 5 mg/kg and about 20 mg/kg bevacizumab antibody. 37. The method of claim 26, wherein the pharmaceutical composition is administered from about once a month to about three times a month. 38. The method of claim 26, wherein the pharmaceutical composition is administered three times per 28 day cycle for at least two cycles.

Details for Patent 10,413,606

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2032-10-01